Portal de Periódicos da CAPES

HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device

2021; Multidisciplinary Digital Publishing Institute; Volume: 13; Issue: 17 Linguagem: Inglês

10.3390/cancers13174446

2072-6694

Cláudia Lopes, Paulina Piairo, Alexandre Chícharo, Sara Abalde‐Cela, Liliana R. Pires, Patrícia Corredeira, Patrícia Alves, Laura Muinelo‐Romay, Luís Costa, Lorena Diéguez,

Microfluidic and Bio-sensing Technologies

HER2 is a prognostic and predictive biomarker in breast cancer, normally assessed in tumour biopsy and used to guide treatment choices. Circulating tumour cells (CTCs) escape the primary tumour and enter the bloodstream, exhibiting great metastatic potential and representing a real-time snapshot of the tumour burden. Liquid biopsy offers the unique opportunity for low invasive sampling in cancer patients and holds the potential to provide valuable information for the clinical management of cancer patients. This study assesses the performance of the RUBYchip™, a microfluidic system for CTC capture based on cell size and deformability, and compares it with the only FDA-approved technology for CTC enumeration, CellSearch